ストックスクリーナーアプリを入手
2.45
0.00%
0.00
前日終値:
$2.45
開ける：
$2.49
24時間の取引高:
33,075
Relative Volume:
0.01
時価総額：
$8.40M
収益：
$3.57M
当期純損益:
$-15.74M
株価収益率:
-0.3526
EPS:
-6.9481
ネットキャッシュフロー:
$-15.77M
1週間 パフォーマンス:
-18.87%
1か月 パフォーマンス:
-27.08%
6か月 パフォーマンス:
-85.70%
1年 パフォーマンス:
-90.67%
1日の値動き範囲:
$2.41
$2.49
1週間の範囲:
$2.30
$3.05
52週間の値動き範囲:
$2.12
$42.00
Icecure Medical Ltd Stock (ICCM) Company Profile
Compare ICCM vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ICCM
Icecure Medical Ltd
|
2.45 | 8.64M | 3.57M | -15.74M | -15.77M | -6.9481 |
ABT
Abbott Laboratories
|
114.68 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
330.90 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.36 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.62 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.50 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Icecure Medical Ltd (ICCM) 最新ニュース
ICCM Looks 87.8% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
IceCure says West Cancer Center IRB clears ChoICE breast cancer cryoablation study - Bitget
IceCure's ProSense Is First and Only for Low-Risk Breast Cancer With FDA Marketing Authorization - Stock Titan
Icecure Medical Ltd (ICCM) (Q2 2026) Earnings Call Highlights: R - GuruFocus
IceCure Medical (ICCM) Q2 2026 Earnings Call Transcript - AOL.ca
IceCure (ICCM) Earnings Report: EPS Misses Its Estimate under the Current Snapshot; Share Response - Vinanet
IceCure Medical Ltd. SEC Filing (Aug 19, 2026) - Stock Titan
IceCure Medical (ICCM) grants 131K RSUs to North America VP - Stock Titan
IceCure Medical : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
IceCure Medical (NASDAQ: ICCM) director lists no shares - Stock Titan
IceCure (NASDAQ: ICCM) VP now holds 106K shares and RSUs - Stock Titan
IceCure Medical (ICCM) awards COO 141K new RSUs - Stock Titan
IceCure Medical (NASDAQ: ICCM) adds 73,890 RSUs to VP HR stake - Stock Titan
IceCure Medical (ICCM) director Chan Vincent leaves board - Stock Titan
ICCM Looks 85.8% Undervalued on GF Value™ - GuruFocus
IceCure Medical director David Salton files initial beneficial ownership statement - Bitget
IceCure Medical (ICCM) expands 2024 employee share incentive reserve - Stock Titan
Armistice Capital (ICCM) reports 300,332 IceCure Medical shares under shared control - Stock Titan
Maxim Group Maintains Icecure Medical(ICCM.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
IceCure Medical (ICCM) Earnings Call zum 2. Quartal 2026: Umsatz im 1. Halbjahr steigt um 45 % - TradingKey
IceCure Medical (ICCM) details 324,802-share warrant issuance and $9.7M potential proceeds - Stock Titan
New studies highlight FDA-approved ProSense cry... - pluang.com
Two papers examine tumor freezing beyond the primary breast tumor - Stock Titan
IceCure highlights 5-year ICE3 breast cancer trial showing 3.1% recurrence rate after cryoablation - Bitget
IceCure Medical Q2 2026 Earnings Call Transcript - MarketBeat
IceCure Medical Ltd Q2 2026 Earnings Call Summary - Yahoo Finance
IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year - GuruFocus
Earnings call transcript: IceCure Medical misses Q2 2026 estimates as shares fall - Investing.com
Icecure Medical Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
IceCure net loss widens to USD 8.78 million in H1 FY26; revenue rises 45% to USD 1.82 million - Bitget
IceCure Medical (Nasdaq: ICCM) lifts H1 revenue 45% but burns cash - Stock Titan
IceCure First-Half 2026 Earnings: 45% Revenue Growth Comes With Wider Losses - TradingKey
IceCure's Active U.S. Install Base Grows About 70%; Cash $12M - Stock Titan
IceCure Medical (ICCM) names David Salton to board as independent director - Stock Titan
IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026 (PR Newswire) - Aktiellt
Earnings To Watch: Icecure Medical Ltd (ICCM) Q2 2026 -- GF Value Sees 452% Upside - GuruFocus
IceCure Medical Shareholders Approve Special Meeting Agenda on August 6, 2026 - The Globe and Mail
IceCure Medical (ICCM) holders approve agenda after adjourned meeting - Stock Titan
IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment - Morningstar
IceCure Medical to Report First Half 2026 Financial and Operatin - GuruFocus
IceCure Medical Adds Adventist Health as U.S. Clinical Site for - GuruFocus
IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026 - Finviz
IceCure Medical Will Discuss Six-Month Results on Aug. 12 - Stock Titan
Price to book forward of IceCure Medical Ltd. – NASDAQ:ICCM - TradingView
IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense - Morningstar
IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Ca - GuruFocus
IceCure Medical Kicks Off its Post-Marketing ChoICE Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site - marketscreener.com
Icecure Medical Ltd (ICCM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Icecure Medical Ltd (ICCM) Institutional Confidence - TradingKey
Icecure Medical Ltd (ICCM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IceCure Medical Kicks Off Post-Marketing ChoICE Study for ProSense Cryoablation in Low-Risk Breast Cancer Treatment at First U.S. Clinical Site - marketscreener.com
Icecure Medical Ltd (ICCM) 財務データ
収益
当期純利益
現金流量
EPS
0.59%
0.75%
大文字化:
|
ボリューム (24 時間):